Sermorelin
Sermorelin is a synthetic version of the first 29 amino acids of human growth-hormone-releasing hormone (GHRH). It acts at the pituitary gland to stimulate the body's own release of growth hormone. Treatment decisions at New Horizon Wellness are individualized and provider-guided.
What Is Sermorelin?
Sermorelin is a GHRH analog that stimulates somatotroph cells in the anterior pituitary to release endogenous growth hormone. Unlike recombinant human growth hormone, sermorelin works upstream by signaling the pituitary rather than supplying growth hormone directly.
Sermorelin was previously marketed in the United States as Geref. FDA records show that the product was discontinued from marketing for reasons other than safety or effectiveness.
How Sermorelin Signals
- Mimics the biologically active portion of natural GHRH
- Binds GHRH receptors in the anterior pituitary
- Stimulates endogenous growth-hormone secretion
- Can increase downstream IGF-1 signaling
- Requires a functioning pituitary response to produce its effect
What Does the Research Show?
Human research confirms that sermorelin can stimulate growth-hormone secretion from the pituitary. Its best-established clinical evidence comes from pediatric growth-hormone deficiency and from its historical use as a diagnostic stimulus of pituitary growth-hormone reserve.
In a multicenter study of growth-hormone-deficient children, once-daily subcutaneous GHRH-(1-29) increased average height velocity during the first year of treatment. Reviews of sermorelin also describe generally good tolerability in those studied populations, with transient facial flushing and injection-site discomfort among the more commonly reported adverse effects.
Evidence supporting contemporary adult wellness uses—such as body composition, sleep, recovery, or anti-aging—is substantially more limited and should not be inferred from pediatric growth studies.
Why Patients Ask About Sermorelin
Goals commonly discussed include:
- Interest in endogenous growth-hormone signaling
- Recovery and performance goals
- Body-composition concerns
- Sleep and broader wellness goals
- Age-related changes in GH and IGF-1
These are discussion areas, not approved indications or guaranteed treatment outcomes.
What to Know
The currently marketed compounded sermorelin products are not FDA-approved products. Compounded drugs do not undergo FDA premarket review for safety, effectiveness, or quality.
The original FDA-approved Geref products are discontinued. FDA determined that they were not withdrawn from sale for reasons of safety or effectiveness.
A provider should review your health history, medications, laboratory findings, treatment goals, and available alternatives before therapy is considered.
Interested in Sermorelin?
Schedule a consultation to discuss your goals, laboratory findings, and whether sermorelin may be appropriate for your care plan.